The PIVI team is comprised of a team of experts based at both The Task Force for Global Health and the Centers for Disease Control (CDC), representing various fields including influenza, epidemiology, vaccines, immunization, program management, communications, and fundraising.
In the fall of 2017, PIVI will convene an Advisory Board made up of leaders from the public and private sectors representing global public health, vaccines, immunization programs and biosecurity. The Advisory Board will support the PIVI leadership with guidance on strategic objectives, input on critical program decisions, as well as rooting PIVI’s work in best practices to ensure that PIVI compliments others’ work in the areas of pandemic preparedness and flu program creation, implementation and strengthening.
Joseph (Joe) serves as Consulting Director of the Partnership for Influenza Vaccine Introduction. He has more than twenty years of experience working in influenza and vaccines, having started his public health career at the CDC as an EIS officer in the Influenza Branch in 1993.
From 1995 to 2005, Joe worked at CDC on viral diseases, with a focus on research and public health activities related to rotavirus disease and rotavirus vaccines to help ensure that rotavirus vaccines were available for children in both the U.S. as well as those living in developing countries. From 2005 – 2017, Joe led the Epidemiology and Prevention Branch of the CDC’s Influenza Division.
In 2017, Joe was named Associate Director for Global Health Affairs in CDC’s Influenza Division. He brings his expertise in influenza and the expertise and resources of his team to PIVI, spearheading the relationships with country partners. He also regularly participates in national and international meetings and technical groups on immunization and influenza.
Mark serves as director of the Center for Vaccine Equity, at The Task Force for Global Health, which manages the Partnership for Influenza Vaccine Introduction. Since 2012 Mark has overseen PIVI’s work to increase access to flu vaccines and help countries launch and test pandemic preparedness programs. From 2004-2012, Mark was co-founder, chief scientific officer, and senior vice president for research and development of TetraLogic Pharmaceuticals. Mark led the team that discovered and developed a novel, best-in-class drug for the treatment of cancer.
Mark also co-founded ViroPharma Inc. and served as vice president of research and development. While there, he led the development of an antipicornavirus agent that culminated in the first clinical demonstration that an antiviral can affect the duration and severity of the common cold.
Susan (Sue) Chu is a Senior Epidemiologist in the Global Immunization Division (GID) at the CDC. She provides expert input on program aspects of immunization for PIVI. Within the CDC, Sue is involved in new vaccine introduction research and evaluation. Her areas of work have involved HIV and Reproductive Health, and the majority of her public health career has focused on immunizations.
From 1997 to 2005, Sue served as the Associate Director for Science in CDC’s National Immunization Program. In 2010 to 2015, she led the research program for the Vaccine Preventable Disease Eradication and Elimination Branch, GID, which established a $4.5 million global immunization research program in five disease-specific areas: polio, measles, rubella, Hepatitis B, and tetanus.
Sue has over 140 publications in peer-reviewed journals and participates on numerous international scientific and program advisory groups.
Kathryn (Katie) is Technical Lead for the Partnership for Influenza Vaccine Introduction (PIVI). She is an epidemiologist within the CDC’s Influenza Division, Epidemiology and Prevention Branch. Katie is involved in CDC’s international influenza activities, including influenza disease burden and vaccine effectiveness projects, as well as initiatives to introduce and expand national influenza vaccination programs. She ensures epidemiological support for PIVI activities via CDC’s network of influenza experts in Atlanta and across the globe.